By vgreene, 14 June, 2019 Breast Cancer Index (BCI): to guide decisions about adjuvant systemic tx2 [ASCO EV-intermediate; REC-moderate]
By vgreene, 14 June, 2019 PAM50: recommended in conjunction w/ other clinicopathologic variables to guide decisions about adjuvant systemic tx2 [ASCO EV-high; REC-strong]
By vgreene, 14 June, 2019 MammaPrint assay: recommended in pts w/ node-negative status [ASCO EV-high; REC-strong] who ALSO have high clinical risk as defined by MINDACT categorization to inform decisions on withholding adjuvant systemic chemotx2
By vgreene, 14 June, 2019 EndoPredict (12-gene risk score): to guide decisions for adjuvant systemic chemotherapy2 [ASCO EV-intermediate; REC-moderate]
By vgreene, 14 June, 2019 If CKD and at risk for CV events, GLP-1 RA may reduce progression of albuminuria, CV events, or both [C]
By vgreene, 14 June, 2019 If diabetic kidney dz, consider SGLT2-I if eGFR ≥30, and especially if >300 mg/g albuminuria, to reduce risk of CKD progression, CV events, or both [A]